Table 2.
Extent of exposure: pooled data from five phase III studies of SC golimumab in RA, PsA and AS
| Placebo±MTX | Golimumab 50 mg±MTX | Golimumab 100 mg±MTX | |
|---|---|---|---|
| Number of treated patients* | 639 | 1249 | 1501 |
| Number of SC injections (mean/median) | 6.6/6.0 | 22.4/22.0 | 27.5/35.0 |
| Weeks of follow-up (mean/median) | 28.1/24.0 | 93.4/100.0 | 115.1/144.6 |
| Cumulative golimumab dose (mean/median), mg | N/A | 1118.6/1100.0 | 2739.9/3500.0 |
| Number (%) of patients by length of golimumab exposure | |||
| <104 weeks | N/A | 663 (53.1) | 604 (40.2) |
| 104 to <156 weeks | N/A | 323 (25.9) | 200 (13.3) |
| ≥156 weeks | N/A | 263 (21.1) | 697 (46.4) |
*Patients may appear in ≥1 treatment column.
AS, ankylosing spondylitis; MTX, methotrexate; N/A, not applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SC, subcutaneous.